Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Senzer

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Investigational New Drugs|June 12, 2014
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neckDaniel W Bowles, Neil Senzer, Diana Hausman, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 6, 2016
Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous DeliveryZhaohui Wang, Christopher M Jay, Courtney Evans, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 12, 2016
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's SarcomaDonald D Rao, Christopher Jay, Zhaohui Wang, et al.
Cancer Gene Therapy|September 23, 2003
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patientsJohn Nemunaitis, Casey Cunningham, Neil Senzer, et al.
Oncology|July 2, 2019
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor ExperienceMatthew N Metzinger, Cherian Verghese, Danae M Hamouda, et al.
Plos One|June 1, 2018
KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplexDonald D Rao, Xiuquan Luo, Zhaohui Wang, et al.
Gene Regulation and Systems Biology|September 30, 2009
Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2)Chris Jay, Gregory Nemunaitis, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumorsLee S Rosen, Neil Senzer, Tarek Mekhail, et al.
Cancer Investigation|September 20, 2006
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancyJohn Nemunaitis, Svetislava J Vukelja, Donald Richards, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2013
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumorsNeil Senzer, John Nemunaitis, Derek Nemunaitis, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Investigational New Drugs|June 12, 2014
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neckDaniel W Bowles, Neil Senzer, Diana Hausman, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|November 6, 2016
Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous DeliveryZhaohui Wang, Christopher M Jay, Courtney Evans, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 12, 2016
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's SarcomaDonald D Rao, Christopher Jay, Zhaohui Wang, et al.
Cancer Gene Therapy|September 23, 2003
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patientsJohn Nemunaitis, Casey Cunningham, Neil Senzer, et al.
Oncology|July 2, 2019
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor ExperienceMatthew N Metzinger, Cherian Verghese, Danae M Hamouda, et al.
Plos One|June 1, 2018
KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplexDonald D Rao, Xiuquan Luo, Zhaohui Wang, et al.
Gene Regulation and Systems Biology|September 30, 2009
Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2)Chris Jay, Gregory Nemunaitis, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumorsLee S Rosen, Neil Senzer, Tarek Mekhail, et al.
Cancer Investigation|September 20, 2006
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancyJohn Nemunaitis, Svetislava J Vukelja, Donald Richards, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2013
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumorsNeil Senzer, John Nemunaitis, Derek Nemunaitis, et al.
Pageof 8